AAAAAA
Results:
1-14
|
Results: 14
Authors:
Basile, VS
Ozdemir, V
Masellis, M
Meltzer, HY
Lieberman, JA
Potkin, SG
Macciardi, FM
Petronis, A
Kennedy, JL
Citation: Vs. Basile et al., Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia, MOL PSYCHI, 6(2), 2001, pp. 230-234
Authors:
Ozdemir, V
Kalow, W
Okey, AB
Lam, MSM
Albers, LJ
Reist, C
Fourie, J
Posner, P
Collins, EJ
Roy, R
Citation: V. Ozdemir et al., Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C -> A polymorphism in intron 1 of the CYP1A2 gene: Effect of grapefruit juice and low-dose fluvoxamine, J CL PSYCH, 21(6), 2001, pp. 603-607
Authors:
Ozdemir, V
Kalow, W
Posner, P
Collins, EJ
Kennedy, JL
Tang, BK
Albers, LJ
Reist, C
Roy, R
Walkes, W
Afra, P
Citation: V. Ozdemir et al., CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia, J CL PSYCH, 21(4), 2001, pp. 398-407
Authors:
Ozdemir, V
Basile, VS
Masellis, M
Kennedy, JL
Citation: V. Ozdemir et al., Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes, J BIOCH BIO, 47(1-2), 2001, pp. 151-157
Authors:
Ozdemir, V
Shear, NH
Kalow, W
Citation: V. Ozdemir et al., What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?, DRUG SAFETY, 24(2), 2001, pp. 75-85
Authors:
Eken, E
Tipirdamaz, S
Gezici, M
Besoluk, K
Ozdemir, V
Citation: E. Eken et al., Conformation of Cisterna chyli in cats (Felis catus), REV MED VET, 152(6), 2001, pp. 463
Authors:
Demir, O
Yazar, E
Altunok, V
Elmas, M
Ozdemir, V
Citation: O. Demir et al., Effect of phenobarbital on antioxidant enzyme activities and blood gas parameters in Balb/C mice, REV MED VET, 152(10), 2001, pp. 723-726
Authors:
Basile, VS
Ozdemir, V
Masellis, M
Walker, ML
Heltzer, HY
Lieberman, JA
Potkin, SG
Alva, G
Kalow, W
Macciardi, FM
Kennedy, JL
Citation: Vs. Basile et al., A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia, MOL PSYCHI, 5(4), 2000, pp. 410-417
Authors:
Ozdemir, V
Kalow, W
Tang, BK
Paterson, AD
Walker, SE
Endrenyi, L
Kashuba, ADM
Citation: V. Ozdemir et al., Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method, PHARMACOGEN, 10(5), 2000, pp. 373-388
Authors:
Albers, LJ
Reist, C
Vu, RL
Fujimoto, K
Ozdemir, V
Helmeste, D
Poland, R
Tang, SW
Citation: Lj. Albers et al., Effect of venlafaxine on imipramine metabolism, PSYCHIAT R, 96(3), 2000, pp. 235-243
Authors:
Masellis, M
Basile, VS
Ozdemir, V
Meltzer, HY
Macciardi, FM
Kennedy, JL
Citation: M. Masellis et al., Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine, BIOL PSYCHI, 47(3), 2000, pp. 252-266
Authors:
Ozdemir, V
Tyndale, RF
Reed, K
Herrmann, N
Sellers, EM
Kalow, W
Naranjo, CA
Citation: V. Ozdemir et al., Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers, J CL PSYCH, 19(5), 1999, pp. 472-475
Authors:
Kalow, W
Ozdemir, V
Tang, BK
Tothfalusi, L
Endrenyi, L
Citation: W. Kalow et al., The science of pharmacological variability: An essay, CLIN PHARM, 66(5), 1999, pp. 445-447
Authors:
Naranjo, CA
Busto, U
Ozdemir, V
Citation: Ca. Naranjo et al., Current clinical assessment and management of drug dependence, PHARM TOXIC, 1999, pp. 244-271
Risultati:
1-14
|